AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 11/06/19

Amneal Pharmaceuticals ( AMRX -18.6% ) inks an agreement with privately held Kashiv BioSciences for exclusive U.S. rights to Phase 2-stage K127 (pyridostigmine) for the treatment of myasthenia gravis , a rare autoimmune disorder characterized by weakness in the skeletal muscles. More ...

Fluidigm (NASDAQ: FLDM ) -31%  on Q3 results . More news on: Fluidigm Corporation, Plantronics, Inc., Amneal Pharmaceuticals, Inc., Stocks on the move, Read more ...

Amneal Pharmaceuticals (NYSE: AMRX ) Q3 results : More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Amneal Pharmaceuticals (NYSE: AMRX ): Q3 Non-GAAP EPS of $0.04 misses by $0.09 ; GAAP EPS of -$2.03 misses by $2.10 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

‒ Q3 2019 Net Revenue of $378 million; GAAP Loss per share of ($2.03); Adjusted Diluted EPS (1) of $0.04 ‒ ‒ Positive Cash Flow from Operations of $140 million ‒ ‒ Executing on Near-Term Strategic Actions to Accelerate Business Performance ...

‒ Expands Amneal’s Central Nervous System (CNS) Focused Development Pipeline with Orphan Drug ‒ Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has entered into a licensing agreement with Kashiv BioSciences, LLC for the development and commer...

AES , ALE , AMRX , ANIP , AYR , BCOR , BKI , BLMN , BR , CARS , CBRE , CNHI , CNR , COTY , CPRI , CRCM , CRL , CSTE , CVIA , CVS , CWEN , CYBR , DEA , DNOW , DOC , ELAN , ENBL , ESPR , FUN , GCP , GEL , GIB , GLOG , GOLD , HUM , HZNP , IMOS , IONS , JE...

Trade uncertainty is likely to remain an issue until improving trade relations between China and the United States results in a signed agreement, creating market opportunities for investors. There's no telling what stocks will pop the most, but our most recent research suggests dividend-payi...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Invega ® (paliperidone) extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg. “We are pleased to have received approval on and launched a generic version of Invega, on...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its third quarter 2019 financial results on Wednesday, November 6, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time ...